Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 31Dermatologic 27Head & Neck 15Gynecologic 10Genitourinary 10Gastrointestinal 6Breast 6Tumor-Agnostic 5CNS 5Other solid neoplasm 4Lymphoid 4Sarcoma 3Plasma cell 3Endocrine 1

Conditions

Solid Tumor 1Malignant Solid Tumor 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × cemiplimab × Other solid neoplasm × Clear all
NCT04626635 2026-04-09

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting
933 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06384807 2026-03-11

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Biohaven Pharmaceuticals, Inc.

Phase 1/2 Recruiting
500 enrolled
Other solid neoplasm

Solid Tumor

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Inimmune Corporation

Phase 1 Recruiting
50 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03192345 2024-08-07

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
161 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡